Eli Lilly Extends AC Immune Tau Pact To Broaden Alzheimer’s Pipeline Potential

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Eli Lilly (NYSE:LLY) and AC Immune have amended their collaboration focused on Tau aggregation inhibitor small molecules for Alzheimer's disease and related neurodegenerative diseases. The updated agreement centers on a next generation Tau aggregation inhibitor program, with plans for IND enabling studies in 2026. The move extends Eli Lilly's R&D activity beyond obesity and diabetes into neurodegeneration, an area with significant unmet medical need.

For investors who mostly associate Eli Lilly with obesity and metabolic drugs, this Tau focused update is a reminder that NYSE:LLY is also active in neurodegeneration. Alzheimer's disease and related disorders continue to attract R&D capital globally, given aging populations and limited treatment options. A small molecule approach to Tau aggregation offers a different angle from more widely discussed amyloid targeting treatments.

This amended collaboration and the plan to enter IND enabling work in 2026 add another longer term element to Eli Lilly's pipeline story. For those tracking the stock, it may be useful to watch how management frames neurodegeneration alongside obesity, diabetes and sleep disorders in future updates, as this could influence how the portfolio is perceived over time.

Stay updated on the most important news stories for Eli Lilly by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Eli Lilly.NYSE:LLY Earnings & Revenue Growth as at Apr 2026

4 things going right for Eli Lilly that this headline doesn't cover.

The amended AC Immune partnership signals that Eli Lilly is still willing to commit capital and attention to Alzheimer’s and broader neurodegeneration, even as obesity and diabetes take most of the headlines. By focusing on next generation small molecules that target Tau aggregation inside brain cells, Lilly is pursuing a differentiated approach versus some large-cap peers focused on amyloid or antibody therapies, such as Biogen and Roche. For you as an investor, this matters less for near term numbers and more for how diversified Eli Lilly’s future product mix could become. IND enabling studies planned for 2026 put this program firmly in the long lead-time bucket, so the key questions are about scientific execution, trial design and how much Lilly is prepared to invest alongside other neuroscience bets like its Centessa sleep deal. Success is uncertain for any early neurodegenerative program, but the updated collaboration keeps Eli Lilly in the conversation around next wave Alzheimer’s mechanisms while sharing risk with a specialist partner.

Story Continues

How This Fits Into The Eli Lilly Narrative

The push into next generation Tau aggregation inhibitors supports the narrative that Eli Lilly wants a meaningful presence in neurodegeneration alongside obesity and diabetes, consistent with commentary around a broad specialty pipeline. At the same time, concentrating more R&D in complex areas such as Alzheimer’s could challenge the narrative if late stage failures or higher than expected costs weigh on the earnings trajectory analysts currently model. The specific focus on intracellular Tau small molecules is not a prominent feature of the existing narrative, so investors following that storyline may not yet be fully factoring in the scientific and funding risk of this collaboration.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Eli Lilly to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

⚠️ Neurodegeneration projects often require long, expensive trials with uncertain outcomes, which can strain R&D budgets and increase the risk of write downs if key studies fail. ⚠️ Analysts have already flagged concerns about high non cash earnings and debt, so layering additional long dated neuroscience commitments on top of obesity expansion could raise questions about capital allocation discipline. 🎁 If the Tau program advances successfully toward the clinic, it could add another potential high value therapy area beyond GLP 1s, helping reduce reliance on a relatively narrow set of obesity and diabetes products. 🎁 Partnering with AC Immune lets Eli Lilly share development risk while accessing specialized Tau science, which can broaden optionality in Alzheimer’s without bearing all early stage costs alone.

What To Watch Going Forward

From here, keep an eye on concrete milestones around the AC Immune collaboration, including when the next generation Tau candidate is selected and whether IND enabling work stays on track for 2026. Any early safety or pharmacology readouts, changes to financial terms, or updates in Lilly’s broader neuroscience commentary will help you judge how important this program is within the portfolio compared with obesity, diabetes and sleep assets. It is also worth tracking competitive moves in Tau targeting from players like Biogen, Roche and Eisai to see how crowded this mechanism becomes over time.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Eli Lilly, head to the community page for Eli Lilly to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include LLY.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments